Sinphar Pharmaceutical Co. Ltd. (1734) AI Stock Analysis

Sinphar Pharmaceutical Co. Ltd.

(TWSE:1734)

Select Model

Rating:69Neutral

Price Target:TWD 33.00▲(9.45% Upside)

Action:initiatedcoverage

Date:11/10/26

The score is primarily supported by improving profitability, moderate leverage, and positive cash generation. Weak technical momentum and volatile free cash flow weigh on the result, while valuation provides moderate support.

Positive Factors

Revenue and Margin Expansion2025's sharp revenue acceleration, alongside stronger gross, EBIT and net margins, indicates improved operating traction. If sustained, this broader earnings base can support reinvestment and strengthen the company's ability to compete over the next several quarters.

Negative Factors

Inconsistent Cash ConversionOperating cash flow was only about 57.8% of net income in 2025, versus about 41.7% in 2024, while FCF growth fell about 161.8%. Such conversion swings can reduce confidence in earnings quality and make internally funded investment less predictable.

Sinphar Pharmaceutical Co. Ltd. (1734) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 6.05B
Dividend Yield: 3.13%
Average Volume (3M): 206.13K
Price to Earnings (P/E): 17.3
Beta (1Y): 0.14
Revenue Growth: 2.44%
EPS Growth: -3.96%
Country: TW
Employees: 1,829
Sector: General
Sector Strength: 55
Industry: Medical - Pharmaceuticals

Sinphar Pharmaceutical Co. Ltd. Business Overview & Revenue Model

Company Description

Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the production, processing, selling, and trading of various medicines, chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Vietnam, Indonesi...

Sinphar Pharmaceutical Co. Ltd. Financial Statement Overview

Summary

Profitability and balance-sheet strength improved substantially, supported by 7.0% revenue growth, a 10.8% net margin, lower leverage, and positive operating and free cash flow. Cash-flow volatility limits the score.

Income Statement

82Very Positive

Balance Sheet

80Positive

Cash Flow

65Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.45B	3.37B	3.15B	2.96B	2.86B	2.43B
Gross Profit	1.52B	1.46B	1.24B	1.09B	1.09B	888.71M
EBITDA	687.37M	689.70M	601.24M	582.94M	539.57M	109.64M
Net Income	351.67M	365.75M	304.70M	375.17M	224.64M	-38.13M
Balance Sheet
Total Assets	6.84B	6.15B	6.30B	6.25B	6.19B	6.22B
Cash, Cash Equivalents and Short-Term Investments	1.60B	994.63M	1.18B	1.08B	1.24B	1.24B
Total Debt	2.05B	1.51B	1.90B	1.95B	1.91B	2.13B
Total Liabilities	3.12B	2.44B	2.75B	2.85B	2.97B	3.14B
Stockholders Equity	3.45B	3.44B	3.26B	3.10B	2.93B	2.72B
Cash Flow
Free Cash Flow	326.35M	383.72M	336.80M	-4.57M	271.85M	-25.90M
Operating Cash Flow	598.46M	584.66M	593.51M	296.37M	425.30M	135.54M
Investing Cash Flow	-259.92M	-224.63M	-391.08M	-334.56M	-124.24M	-205.60M
Financing Cash Flow	195.09M	-576.03M	-209.08M	-106.84M	-263.32M	122.95M

Sinphar Pharmaceutical Co. Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:1734 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:4166	70Outperform	TWD 5.47B	22.78	―	―	―	―
TW:1734	69Neutral	TWD 6.07B	17.33	―	3.13%	2.44%	-3.96%
TW:4746	64Neutral	TWD 5.43B	11.42	―	6.61%	-2.71%	―
TW:4167	60Neutral	TWD 6.30B	7.86	―	4.18%	-0.05%	64.82%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4119	48Neutral	TWD 5.85B	95.69	―	1.55%	-18.83%	-87.54%
TW:1799	45Neutral	TWD 6.24B	-264.14	―	―	59.53%	83.16%

* General Sector Average

Performance Comparison

TW:1734 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:1734	Sinphar Pharmaceutical Co. Ltd.	30.15	1.89	6.71%
TW:1799	Easywell Biomedicals, Inc.	24.55	-7.65	-23.76%
TW:4119	SCI Pharmtech Corp.	48.50	-0.42	-0.85%
TW:4166	Orient Pharma Co., Ltd.	22.55	-1.95	-7.96%
TW:4167	Savior Lifetec Corp.	19.25	2.57	15.39%
TW:4746	Formosa Laboratories, Inc.	45.40	-15.89	-25.92%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Sinphar Pharmaceutical Co. Ltd. AI Stock Analysis